Progression of human cutaneous primary melanoma is, among others, accompanied by de novo expression of activated leukocyte cell adhesion molecule (ALCAM/CD166) and enhanced activity of proteolytic cascades in the invasive, vertical growth phase (VGP) of lesions. The homophilic cell adhesion function of wild-type ALCAM mediates homotypic clustering of melanoma cells and would, thus, antagonize cell release from the primary tumor, an early prerequisite for metastasis. Stable transfection of a transmembrane, amino-terminally truncated ALCAM (DN-ALCAM) into metastatic cells diminished cell clustering mediated by wild-type ALCAM. We have addressed the biological effects of DN-ALCAM on tumorigenicity and found that the relief of cell clustering constraints promoted motility in vitro and the transition from expansive tumor growth to tissue invasion in reconstructed skin in culture. In a transplant tumor model, the changes were reflected in reduced subcutaneous tumor growth and in accelerated, spontaneous lung metastasis. These data indicate that the intact cell adhesion function of ALCAM may both favor primary tumor growth and represent a rate-limiting step for tissue invasion from VGP melanoma. ALCAM induction could, thus, provide an attractive target for proteolysis as a part of a more complex cellular program that couples growth and migration and facilitates dissemination.
Cutaneous melanoma is a malignant tumor of the pigmented cells (Chin et al, 1998) . The current lifetime risk for developing any kind of melanoma is one in 75 for a Caucasian in the United States and this incidence will continue to rise for at least the next 10-20 y (Rigel et al, 1996) . Melanoma is notorious for an early metastasizing phenotype and lack of response to current therapeutics. This is reflected in poor 5-y survival rates (o10%) of patients diagnosed with advanced primary melanoma (Herlyn, 1993; Balch et al, 2001) . Understanding the molecular events that mark the transition from non-metastasizing to metastasizing melanoma is, therefore, of utmost importance.
In about one-third of the cases, melanomagenesis progresses through a series of steps starting with melanoblasts, melanocytes, or benign melanocytic nevi and develops via radial (RGP) and vertical growth phase (VGP) primary tumors to metastases (Clark et al, 1984; Herlyn, 1999) .
During the past 15 y, several adhesion molecules that are expressed in specific stages of melanoma progression have been identified, e.g., cadherins, integrins, and immunoglobulin cell adhesion molecules (Ig-CAM; for a review see Meier et al, 1999) . Expression of activated leukocyte cell adhesion molecule (ALCAM/MEMD/CD166) distinguishes the invasive and metastasizing VGP melanoma from noninvasive and non-metastasizing RGP melanoma (Van Kempen et al, 2000) . ALCAM expression can only be detected in a subset of cells at the invasive front of these malignant tumors. Additionally, ALCAM expression is observed in various carcinoma cell lines including breast, prostate, colon, and bladder (Degen et al, 1998 and our unpublished data) . Therefore, elucidating the functional involvement of ALCAM in melanoma progression may also provide new insights into other types of cancer.
ALCAM is a transmembrane protein and a member of the Ig superfamily (reviewed in Isake and Horton, 2000; Swart, 2002) . It has approximately 80% homology with the chicken neural cell adhesion molecule BEN/SC1/DM-GRASP (Burns et al, 1991; Tanaka et al, 1991; Pourquie et al, 1992) and approximately 27% identity and 38% similarity with the human melanoma cell adhesion molecule MUC18/Mel-CAM/ CD146 (Lehmann et al, 1989) . ALCAM, first identified as a CD6 ligand (Bowen et al, 1995) , is involved in hematopoiesis (Cortes et al, 2000; Nelissen et al, 2000a) , neurite extension (Sekine-Aizawa et al, 1998) , osteogenesis (Bruder et al, 1998) , and embryonal implantation in the uterus (Fujiwara et al, 2003) . Both heterophilic (ALCAM-CD6) interactions and homophilic (ALCAM-ALCAM) interactions have been described (Bowen et al, 1995; Degen et al, 1998; Nelissen et al, 2000b) . In human melanoma cell lines, ALCAM facilitates tumor cell aggregation via homophilic interactions (Degen et al, 1998) . ALCAM comprises five extracellular Ig domains (D1-5): two amino-terminal, membrane-distal, variable (V-) type domains followed by three membrane-proximal, constant (C 2 -) type domains (VVC 2 C 2 C 2 ). It further comprises a transmembrane domain and a short carboxyterminal cytoplasmic tail. ALCAM-mediated intercellular adhesion involves interactions between opposing aminoterminal D1 domains of receptor molecules on different cells. ALCAM-mediated adhesion is further strengthened by lateral oligomerization of neighboring molecules on the cell surface involving the membrane proximal domains D4-5 (Van Kempen et al, 2001 ). This bimodular structure supports the formation of a tight network of ALCAM interactions in regions of cell-cell contact ( Fig 1A) . The expression of ALCAM at the invasive front of VGP melanoma lesions, however, poses the paradox of strong cellular adhesion in the very part of the tumor notorious for tumor cell dissemination and subsequent metastasis.
Modulation of cell adhesion is required to pass through the successive stages of the metastatic cascade. One may anticipate that an increase in homotypic tumor cell clustering should, presumably, hamper cell release from a primary lesion. By contrast, the formation of tumor cell emboli could favor cell survival during later stages of metastasis. To gain insight in the positive and negative effects of homotypic cell clustering on tumorigenesis, we have compared the malignant properties of BLM, a metastatic melanoma cell line with endogenous expression of wild-type ALCAM, and a series of BLM clones that additionally express recombinant, amino-terminally truncated ALCAM (DN-ALCAM) to attenuate homotypic cell clustering (Fig 1B) . This analysis revealed dual effects, as diminished cell clustering was apparently unfavorable for primary tumor growth whereas it enhanced cell motility and metastasis.
Results
Reduced ALCAM-mediated cell adhesion increases melanoma cell motility To interfere with homotypic cell clustering we overexpressed a transmembrane, aminoterminally truncated ALCAM construct (DN-ALCAM) in BLM cells that endogenously express wild-type ALCAM (D1-5). DN-ALCAM lacks the extracellular ligand-binding domains D1-2 but retains the oligomerizing function of domains D3-5. The truncated molecule, with an apparent molecular mass of 90 kDa, interfered in the formation of a tight ALCAM network, thereby reducing cellular adhesion in a concentration-dependent manner (Fig 2; compare Van Kempen et al, 2001) . To test whether cells with reduced ALCAM-mediated adhesion would have a more mobile phenotype as a consequence of decreased anchoring to their neighbors, an in vitro wound-healing assay was performed by inflicting a ''wound'' on a confluent monolayer of cells. The time interval needed to close the gap was monitored for control and DN-ALCAM-transfected cells. It was observed that DN-ALCAM expression by BLM cells slightly increased cell motility compared with vector control cells (Fig 3) . Transfection of DN-ALCAM into 530 cells (a non-metastatic, ALCAM-negative melanoma cell line) did not affect the virtual lack of motility of these cells. Thus, reduction of wildtype ALCAM-mediated cell-to-cell contacts increased cell motility in vitro.
Attenuation of ALCAM cell adhesion and effects on melanoma growth in skin reconstructs It is generally accepted that loss of cell-cell adhesion and a concomitant increase in cell motility favor the invasive potential of tumor cells (Hanahan and Weinberg, 2000) . Therefore, the invasive capacity of melanoma cells expressing DN-ALCAM was tested in skin reconstructs. Control cells transfected with empty vector (BLM/CTRL, expressing wild-type ALCAM) formed massive clusters of cells and band-like aggregates within the epidermis at the epidermal-dermal junction and in the upper dermis (Fig 4A) . Complete disruption of the epidermal architecture reflected the expansive and moderately invasive growth phenotype of these BLM/CTRL cells. In contrast, DN-ALCAM expressing BLM cells (BLM/DN-ALCAM: expressing DN-ALCAM in addition to wild-type ALCAM) displayed a highly invasive phenotype and localized in the dermis, thereby leaving the epidermis intact (Fig 4B) . These vertically oriented cells steadily migrated or disseminated as slender tumor cell strands or single cells deep into the dermal compartment (Fig 4C) , whereas individual, horizontally oriented BLM/CTRL cells moderately invaded into the upper dermis (Fig 4A and D) . Inhibition of ALCAM-mediated cell clustering via DN-ALCAM, thus, revealed the invading potential of the human melanoma cell line BLM.
Partially impaired ALCAM-mediated adhesion and primary xenograft growth In order to study whether impairing ALCAM-mediated cell adhesion by DN-ALCAM affects tumorigenic properties, BLM/DN-ALCAM cells were subcutaneously injected into nude mice. Monitoring local tumor growth, it was observed that BLM/DN-ALCAM cells displayed a delay in tumor take and decreased growth of the subcutaneous tumors compared with BLM/CRTL cells (Fig 5A) . In additional control experiments, the transfection of either wild-type ALCAM or DN-ALCAM into 530 melanoma cells did not significantly alter their subcutaneous growth.
In cell culture, no differences were observed in cell proliferation rates between BLM/DN-ALCAM and BLM/CRTL cells (data not shown). Analysis of the tumors obtained after euthanizing the mice (Fig 5B) disclosed neither differences in cell proliferation indices (I proliferation , F ¼ 1.06, p ¼ 0.38, one-way analysis of variance), nor apoptosis indices (I apoptosis , F ¼ 0.89, p ¼ 0.44, one-way analysis of variance) nor necrosis (not shown) indicating that the decreased primary tumor growth cannot be ascribed to a disrupted balance between cell gain and cell death.
Partially impaired ALCAM-mediated adhesion and lung metastasis An alternative explanation for reduced primary tumor growth could be provided by the difference in the migratory potential of the cells as observed in reconstructed skin in culture (Fig 3) . To obtain a more complete picture and to collect larger numbers of subcutaneous tumors of different sizes, we varied the lifetime of mice after inoculation of the tumor cells. An overview of all data (scoring subcutaneous tumor size, metastasis rate, and lifetime after subcutaneous inoculation of the melanoma cells) is presented in Table I . Rapid tumor cell dissemination may explain the reduced growth of subcutaneous tumors derived from BLM/DN-ALCAM as these cells already gave rise to lung metastasis in a considerable number of mice at a relatively small tumor mass, i.e., less than 1.5 g, whereas lung metastasis of the control cells occurred only at tumor masses exceeding 3 g (Table I ). The numbers in Table II showed that the differences found in metastasis frequencies were statistically significant (po0.05; w 2 test). In additional control experiments, we found that transfection of wild-type ALCAM or DN-ALCAM into 530 melanoma cells did not alter the non-metastatic phenotype of these cells. Our data suggest that subcutaneous tumor growth is rate limiting for metastasis formation of control BLM cells, which have a wild-type ALCAM cell adhesion function.
Subcutaneous tumor formation was hampered after additional expression of DN-ALCAM and consequent attenuation of BLM cell clustering (compare with Figs 2 and 5). Unexpectedly, diminished growth of subcutaneous tumors was not accompanied by an apparent decrease in malignancy (Table I) . On the contrary, the number of metastatic lesions in the lung sections scored by microscopic analysis also revealed that the presence of DN-ALCAM rather reduced the need of subcutaneous tumor formation prior to metastasis. The number of metastatic lesions was generally higher after inoculation of BLM/DN-ALCAM cells (4.2 and 5.1 lung lesions on average per positive mouse, respectively; Table II) than after inoculation of control BLM cells (3.2 lung lesions on average per positive mouse; Table II ). These observations underscored the interpretation that the recombinant generation of DN-ALCAM in BLM cells accelerated the dissemination process.
Discussion
Melanoma development advances from superficially spreading tumor growth in the epidermis to subsequent invasive growth into the dermis and culminates in the formation of distant metastases. Human melanoma progression is accompanied by de novo expression of the homophilic cell-cell adhesion molecule ALCAM/CD166 at the invasive front of VGP tumors (Van Kempen et al, 2000) . It is generally accepted that onset of metastatic spread implies release of cells from the primary tumor mass (Hanahan and Weinberg, 2000) . This poses a paradox since the cell adhesion function of wild-type ALCAM actually promotes tumor cell clustering and would, thus, antagonize cell release from the primary tumor. Attenuation of cell clustering promoted by wild-type ALCAM can be achieved by expression of transmembrane, amino-terminally truncated ALCAM (DN-ALCAM), which lacks the cell adhesion function (Fig 1; Van Kempen et al, 2001 ). Here we show that the resulting relief of clustering constraints favors tumor cell motility in vitro (Figs 2 and 3 ) and the transition from expansive tumor growth to rapid dermal invasion in reconstructed skin in culture (Fig 4) . Furthermore, the presence of DN-ALCAM interferes with subcutaneous The malignant properties of control BLM cells (expressing wild-type ALCAM) and transfected BLM cells (expressing DN-ALCAM in addition to wildtype ALCAM) were analyzed for subcutaneous tumor growth and spontaneous metastasis in nude mice. Series of five animals were subcutaneously inoculated with one line of melanoma cells as described in Materials and Methods. In a first experiment all matched series of animals were simultaneously euthanized when one of the primary tumors reached the maximally tolerated size (this occurred after 42 d; incubation). In successive experiments the incubation time was either limited to 32 d to collect more small tumors (o 3 g) for the control group or prolonged to 48 and 52 d to achieve maximally tolerated tumor size in the series of BLM/DN-ALCAM tumors. The four series of control cells included BLM cell clones transfected with the empty expression vector and untransfected BLM cells. The six series of transfected BLM/DN-ALCAM cells were executed with two of the independently isolated cell clones (BLM/DN-ALCAM-1, -2). Tumor take in all animal series was 100%. In four cases (two controls and two transfectants) the quality of the lung tissue did not allow microscopic analysis to score metastasis and these animals were not included in the table.
tumor growth in a nude mouse model (Fig 5) and lowers the threshold of subcutaneous tumor growth prior to metastasis (Tables I and II) . Taken together with previously published reports (Van Kempen et al, 2000 , the data provide evidence that stepwise modulation of ALCAM-mediated cell adhesion is involved in melanoma metastasis.
Reduction of ALCAM-mediated adhesion via DN-ALCAM resulted in less adhesive and more mobile tumor cells. In cultured skin reconstructs (Fig 4) , metastatic BLM/CTRL cells (expressing wild-type ALCAM) disrupted the epidermal architecture as a result of massive and expansive growth in the epidermis and moderately invaded the upper dermis. In contrast, BLM/DN-ALCAM cells (expressing DN-ALCAM in addition to wild-type ALCAM) steadily migrated deep into the dermis as single cells or slender tumor cell strands, leaving the epidermis intact. The biological behavior of BLM/CTRL cells strikingly resembled the properties of the human vertical growth phase melanoma cell line WM793 in skin reconstructs, which displayed comparable cell clusters within the epidermis, at the epidermal-dermal junction and upper dermis (Meier et al, 2000) . On the other hand, the biological behavior of BLM/DN-ALCAM cells closely resembled the highly metastatic human melanoma cell line WM852 with its typical aggressive, vertical, invasive growth of individual melanoma cells deep into the dermal part of the skin reconstructs (Meier et al, 2000) .
When inoculating cells co-expressing endogenous wildtype ALCAM and ectopic DN-ALCAM into nude mice, the reduced subcutaneous tumor growth observed (Fig 5A) could not be explained by changes in either tumor cell proliferation, necrosis, or apoptosis (Fig 5B) . A feasible explanation for the reduced subcutaneous growth would be that BLM/DN-ALCAM cells were continuously released even before outgrowth of a substantial subcutaneous tumor mass. The observation that subcutaneous inoculation of BLM/DN-ALCAM cells into nude mice already gave rise to the formation of lung metastases at a relatively small tumor mass, is in agreement with this explanation. As BLM/CTRL cells did not form lung metastases at these small sizes (Tables I and II) , we conclude that the decreased subcutaneous tumor growth is caused by rapid and continuous release of cells from the subcutaneous tumor as a consequence of less adhesive and more motile tumor cells.
Thus, our data suggest that ALCAM-mediated adhesion represents a rate-limiting step in the transition from expansive primary tumor growth to invasion of the surrounding tissue, i.e., the initial step in the metastatic cascade.
Considering their relative structures, it has not escaped our notice that DN-ALCAM may be generated from wildtype ALCAM by proteolysis (see cell adhesion model; Fig 1) . It is generally known that expression and activity of a variety of extracellular and cell-surface proteinases are upregulated in tumors and that elevated proteinase levels strongly correlate with the in vitro invasive behavior of tumor cells, including melanoma cells (Werb, 1997; Lochter et al, 1998; Hofmann et al, 2000a; McCawley and Matrisian, 2000, Sternlicht and Werb, 2001; Coussens et al, 2002; Egeblad and Werb, 2002; Dennhofer et al, 2003) . Progression of human cutaneous primary melanoma was reported to coincide with increased expression and activation of matrix metalloproteinase (MMP)-2 (Kurschat et al, 1999 (Kurschat et al, , 2002 Hofmann et al, 2000b) . Although MMP are best known for their capacity to cleave virtually all extracellular matrix proteins, recent literature reports also demonstrate their involvement in the release of growth factors that are sequestered in the matrix, cleavage of growth factor receptors on the cell plasma membrane (Werb, 1997; Bergers and Coussens, 2000) , and in modulating cellular adhesion and cell mobility (Kajita et al, 2001; Mechtersheimer et al, 2001; Noë et al, 2001) . Specific shedding of membrane receptors by these proteinases may be an integral part of cell-cell communication and essential for early stages of neoplastic progression (Vu and Werb, 2000) . We like to propose that the applied, recombinant expression of DN-ALCAM in BLM cells may be a paradigm of proteolytic mimicry. Expression of recombinant degradation products may stabilize short-lived cleavage intermediates and, thus, facilitate the biological analysis of highly transitory cell responses. It will be worthwhile to clarify the conjectured role of proteolysis in modulating ALCAM functions.
Because attenuation of ALCAM-mediated cell-cell adhesion in human melanoma cells positively contributes to metastasis, the question arises why and how de novo ALCAM expression in VGP melanoma contributes to tumor The data from Table I were pooled on the basis of subcutaneous tumor size. The comparison of controls (w.t. ALCAM) and transfectants (w.t. ALCAM þ DN-ALCAM) revealed a statistically significant increase in metastasic lesions derived from small tumors (o3 g) of the DN-ALCAM transfectants (po0.05; wprogression. All attempts failed to select for BLM cells with diminished ALCAM expression via application of repeated cycles of FACS selection and anti-sense techniques (our unpublished results), suggesting that ALCAM could be required for sustained cell proliferation in these cells. Additionally, developmental biology studies show that ALCAM expression generally occurs in cells undergoing proliferation: e.g., ALCAM is expressed in the growth cone of extending neurons Sekine-Aizawa et al, 1998) and in hematopoietic progenitor cells with high proliferative potential (Uchida et al, 1997) . Furthermore, the avian orthologue of ALCAM, DM-GRASP, may be involved in the growth of v-rel-positive tumor cells (Zhang et al, 1995) . In the metastatic cascade analyzed here, attenuation of the ALCAM cell adhesion function apparently impairs primary tumor growth and favors actual cell release from the primary tumor. Although tumor growth and metastasis are generally related, our observations indicate that cell proliferation and invasion may represent disconnected phenotypic events. This phenomenon is a rather rare or neglected aspect in metastasis research, but it could well relate to the aggressive malignancy of melanoma and the notorious metastatic potential of thin lesions. Tuning cell growth and invasion is inherent to normal development and, presumably, requires coordination via molecular switches. If ALCAM would represent such a switch, its expression in melanoma progression could reflect the pathological onset of a genomic program that coordinates cellular proliferation and migration. This hypothesis is open for further experimental verification.
Materials and Methods
Cell lines The adherent human melanoma cell lines BLM and 530 (Van Muijen et al, 1991) were grown as monolayers in Dulbecco's modified Eagle's medium (DMEM) as described before (Degen et al, 1998) . BLM cells transfected with amino-terminally truncated ALCAM (DN-ALCAM) and 530 cells transfected with wild-type ALCAM were cultured as described previously (Degen et al, 1998; Van Kempen et al, 2001) . Regular tests confirmed that cell lines were free of mycoplasma contamination.
Transfection FuGENE-6 transfection reagent (Roche Diagnostics, Mannheim, Germany) was used to transfect the human melanoma cell lines according to the manufacturer's protocol. In brief, a mixture of FuGENE-6 and circular DNA (3 mL and 0.5 mg, respectively) was added drop wise to a 40% confluent monolayer in medium. After 48 h, medium was replaced with selection medium (medium þ 1 mg per mL G418). Neomycin resistant colonies were expanded and maintained in medium supplemented with 0.5 mg per mL G418 (Life Technologies, Breda, The Netherlands).
Flow cytometry: Cell surface expression and aggregation assay Cells (2 Â 10 5 ) were incubated with mouse monoclonal antibody AZN-L50 that recognizes the membrane proximal ALCAM domains D4-5 (Nelissen et al, 2000a; Van Kempen et al, 2001 ) at 4 mg per mL in (phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) and 0.05% NaN 3 ) for 30 min at 41C. Cells were washed three times with this buffer and further incubated with FITC-conjugated goat anti-mouse IgG antibody (Dako, Glostrup, Denmark) for 30 min at 41C. After washing, positive cells were detected using an FACScan (Becton Dickinson, Mountain View, California) and the mean fluorescence intensity was determined.
The aggregation capacity of human melanoma cell lines was measured by a double colored assay as described previously (Degen et al, 1998) . Briefly, two separate cell suspensions were labeled fluorescent green or fluorescent red with 5,6-sulfofluorescein diacetate (50 mg per mL in DMEM/fetal calf serum (FCS), Molecular Probes, Junction City, Oregon) or hydroethidine (40 mg per mL in DMEM/FCS, Polysciences, Warrington, Pennsylvania), respectively. Following extensive washing, cells were mixed in equal amounts and allowed to aggregate at 371C for 30 min. After incubation, cells were fixed by adding paraformaldehyde to a final concentration of 0.5% (v/v) and subsequently analyzed by flow cytometry. Aggregation capacity was expressed as the percentage of double colored events of the total of red plus green events.
Wound-healing assay Using a pipette tip, a ''wound'' was inflicted to a confluent monolayer of cells. After removal of the detached cells by washing with warm medium, the Petri dishes were returned to 371C. The gap width was measured using an Olympus BH-2 microscope and DP10 camera (Olympus, Hamburg, Germany) after 2 h to allow spreading of the cells and every 2 h thereafter. Images were analyzed using AnalySIS software (Soft Imaging Systems, Mü nster, Germany). The duration of the experiment did not exceed the doubling time of the cells tested (18 h, unpublished data). The gap width was plotted as function of time.
Cell invasion in three-dimensional skin reconstructs Invasion of melanoma cells was tested in skin reconstructs as described previously (Meier et al, 2000) . In brief, human foreskin dermal fibroblasts in rat tail collagen were placed on a precast collagen gel on day 0. During 6 d of submerged culture, constriction of the collagen gels yielded a concave surface, which served as a cradle for seeding of epidermal and melanocytic cells. Melanoma cells mixed with keratinocytes at a 1:5 ratio were seeded onto the dermal constructs (day 6). After another 5 d of submerged culture (day 11), the gel constructs were lifted to the air-liquid level for an additional 10 d to allow stratification of epidermal keratinocytes. The reconstructs were then harvested (day 21), fixed in paraformaldehyde, embedded in paraffin, sectioned, and stained with HMB45 melanocytic marker. Normal melanocytes localized within the stratum basale of the epidermis are positive. BLM cells are HMB45 negative.
In vivo local tumor growth and metastasis Animal studies were approved by the Institutional Review Board for animal experiments. Female BALB/c athymic nude mice (nu/nu) were bred in the nude mice facility of the Central Animal Laboratory, University of Nijmegen, The Netherlands. Animals were kept under specified pathogen-free conditions and used when 4-6 wk old.
Tumor cells were harvested using trypsin/EDTA, washed in PBS and suspended in PBS at 2.5 Â 10 7 cells per mL and 100 mL of cell suspension was inoculated subcutaneously above the lateral thoracic wall (Van Muijen et al, 1991) . Mice were inspected twice a week for general condition and local tumor growth was monitored. The animals were euthanized at the indicated times. Following euthanization, lungs were prepared with TissueTech Sakuro compound (Bayer B.V., Mijdrecht, The Netherlands), fixed in 4% neutral formalin and finally embedded in paraffin for microscopic examination of hematoxylin-and eosin-stained 4 mm sections.
In situ proliferation and apoptosis detection Tumor cell proliferation was detected via immunohistochemical staining of paraffin-embedded tumors. The mouse monoclonal antibody MIB-1 (Immunotech, Beckman Coulter, Mijdrecht, The Netherlands) is directed against the Ki67 nuclear protein, which is expressed in proliferating cells during late G1-, S-, M-, and G2-phases of the cell cycle, whereas cells in the G0 (quiesent phase) are negative for this protein (Gerdes et al, 1984) . Tumor sections (5 mm) were deparaffinated in xylene (two times 5 min) and, subsequently, in absolute ethanol (three times 5 min). Slides were boiled twice in 0.1 M citrate buffer (pH 6.0) for 5 min in a microwave and rinsed with PBS supplemented with 0.1% BSA. Following blocking of non-specific sites via incubation in normal horse serum (Vector Laboratories, Burlingame, California) for 20 min, sections were incubated with monoclonal antibody (mAb) anti-MIB-1 for 1 h at room temperature. After washing the slides with PBS/0.1% BSA, they were incubated with biotin-conjugated horse anti-mouse antibody (Dako) for 30 min. After subsequent washing with PBS/ 0.1% BSA, the avidin-biotin complex was formed using the Vectastain elite kit (Vector Laboratories) and developed by incubating the slides with diaminobenzidine (Pierce, Rockford, Illinois) for 10 min. Sections were briefly counterstained with hemateine. Using the Weibel-2 graticule (Graticules Ltd, Kent, UK), the proliferation index was scored by counting MIB-1-positive cells. Randomly chosen fields within one tumor lesion were counted until the average of MIB-1-positive cells did not change after counting additional fields. Generally, after scoring seven fields, a stable average was obtained.
Apoptosis was detected by in situ TdT-mediated dUTP nick end labeling (TUNEL). Tumor sections of 5 mm were deparaffinated in xylene, rehydrated, washed in PBS, and digested with 40 mg per mL Proteinase K (Sigma, St Louis, Missouri) in PBS for 15 min at 251C. The TUNEL reaction was performed according to the manufacturer's instructions (Intergen, Oxford, UK), developed with diaminobenzidine (Pierce) and counterstained with 0.5% (w/v) methyl green in 0.1 M sodium acetate, pH 4.0. The apoptotic index was determined on five or more fields (corresponding to 41500 cells) from each tumor lesion. The fields were randomly chosen within regions with scattered apoptosis as described (Toft and Arends, 1997) . The ''STATGRAPHICS plus 4.1'' software package was used to perform statistical calculations (one-way analysis of variance). 
